¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"steroid rebound phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® rebound phenomenon ÇÑ±Û ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
¼³¸í   
  ¼Ò³ú ±â´ÉÀå¾Ö¿¡¼­ »çÁöÀÇ ´ëÇ×±ÙÀ° »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀǠ¡Èķμ­, È¯ÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇϰԠġ¸é Á¤»óÀΠ°æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Âµ¥ ºñÇÏ¿© È¯ÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
¿µ¹® steroid ÇÑ±Û ½ºÅ×·ÎÀ̵å
¼³¸í   
  Hydrogenated cyclopentanoperhydrophenanthrene ring systemÀ¸·Î ±¸¼ºµÈ ºÐÀÚ. »ýü³»¿¡¼­ Áß¿äÇÑ ½ºÅ×·ÎÀ̵å´Â ºÎ½Å°ÑÁú¿¡¼­ »ý¼ºµÇ´Â ½ºÅ×·ÎÀ̵å È£¸£¸óÀ̸破ç´ë»ç¿¡ °ü¿©Çϴ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å(glucocorticoid), ¿°·ù´ë»ç(ÀÎü³» Á¸ÀçÇϴ ¿°ºÐ¼ººÐ(NaCl, KCl, NaOH µî)À» Á¶ÀýÇϴ ´ë»ç)¿¡ °ü¿©Çϴ ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵å(mineralocorticoid), ¼ºÈ£¸£¸ó(ÀÎüÀÇ ¼º¹ß´Þ¿¡ °ü¿©)ÀÇ ¼¼ °¡ÁöÀÌ´Ù.
  
  ½ºÅ×·ÎÀ̵å È£¸£¸óÀº ºÎ½ÅÇÇÁú¿¡¼­ ÄÝ·¹½ºÅ×·ÑÀ» Àç·á·Î ÇÏ¿© º¹ÀâÇÑ ÇÕ¼º´Ü°è¸¦ °ÅÃÄ ÇÕ¼ºµÈ´Ù. ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å´Â ³úÇϼöü¿¡¼­ ºÐºñµÇ´Â ºÎ½Å°ÑÁúÀڱؠȣ¸£¸ó(ACTH)¿¡ ÀÇÇØ »ý¼º°ú ºÐºñ°¡ ÀÌ·ç¾îÁö³ª ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵å´Â ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(½ÅÀå¿¡¼­ ÀÎü³» ¿°ºÐÀÌ ºÎÁ·½Ã ·¹´ÑÀÌ ºÐºñµÇ°í, ÀÌ ÀÚ±ØÀº ºÎ½ÅÀ¸·Î ÀüÇØÁ® ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵åÀΠ¾ÈÁö¿ÀÅÙ½ÅÀ» ºÐºñÇϰԠµÊ)ÀÇ Àڱؿ¡ ÀÇÇØ ºÐºñµÈ´Ù. ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å´Â transcortin°ú °áÇÕÇÏ¿© ¿î¹ÝµÇ¸ç ¹Ý°¨±â´Â Çѽð£ Á¤µµÀ̳ª ¿°·ùÄÚ¸£Æ¼ÄÚÀ̵å´Â ´ëºÎºÐÀÌ ´Ü¹éÁú°ú °áÇÕÇÏÁö ¾Ê°í À¯¸®ÇüÀ¸·Î ³²¾ÆÀ־ݰ¨±â´Â 20ºÐ¿¡ ºÒ°úÇÏ´Ù. À̵éÀÌ °£¿¡ µµ´ÞÇϸé glucuronic acid¿¡ °áÇÕÇÏ¿© ¹è¼³µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • rebound
    1. ¹Ýµ¿- 2. ¹Ýµ¿
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´ç(Áõ)
  • rebound nystagmus
    ¹Ýµ¿´«¶³¸², ¹Ýµ¿¾ÈÁø
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • adrenal steroid
    ºÎ½Å½ºÅ×·ÎÀ̵å
  • adrenocortical steroid
    ºÎ½Å°ÑÁú½ºÅ×·ÎÀ̵å, ºÎ½ÅÇÇÁú½ºÅ×·ÎÀ̵å
  • anabolic steroid
    ÇÕ¼º´ë»ç½ºÅ×·ÎÀ̵å
  • androgenic steroid
    ³²¼ºÈ­½ºÅ×·ÎÀ̵å
  • gonadal steroid
    »ý½Ä»ù½ºÅ×·ÎÀ̵å, ¼º¼±½ºÅ×·ÎÀ̵å
  • gonadal steroid-binding globulin
    »ý½Ä»ù½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • steroid
    ½ºÅ×·ÎÀ̵å
  • steroid cataract
    ½ºÅ×·ÎÀ̵å¹é³»Àå
  • steroid cell tumor
    ½ºÅ×·ÎÀ̵弼Æ÷Á¾¾ç
  • steroid hormone
    ½ºÅ×·ÎÀ̵åÈ£¸£¸ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
  • rebound
    ¹Ýµ¿, ¹Ýµ¿-
  • steroid
    ½ºÅ×·ÎÀ̵å
  • adrenocortical steroid
    ºÎ½Å°ÑÁú½ºÅ×·ÎÀ̵å, ºÎ½ÅÇÇÁú½ºÅ×·ÎÀ̵å
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • phenomenon
    Çö»ó
  • phantom phenomenon
    ÇêÇö»ó, ȯ»óÇö»ó
  • recruitment phenomenon
    Á¡ÁõÇö»ó, ´©°¡Çö»ó, º¸ÃæÇö»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound phenomenon
    ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´çÁõ
  • rebound hypertension
    ¹Ýµ¿°íÇ÷¾Ð
  • rebound nystagmus
    ¹Ýµ¿´«¶³¸²
  • rebound
    ¹Ýµ¿¼º, ¹Ý¹ß, ¹Ýµ¿
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë, µÇƦÅëÁõ
  • adrenal steroid
    ºÎ½Å½ºÅ×·ÎÀ̵å
  • adrenocortical steroid
    ºÎ½Å°ÑÁú½ºÅ×·ÎÀ̵å, ºÎ½ÅÇÇÁú½ºÅ×·ÎÀ̵å
  • anabolic steroid
    ´Ü¹éµ¿È­½ºÅ×·ÎÀ̵å
  • androgenic steroid
    ³²¼ºÈ­½ºÅ×·ÎÀ̵å
  • steroid-induced atrophy
    ½ºÅ×·ÎÀ̵åÀ§Ãà
  • steroid cataract
    ½ºÅ×·ÎÀ̵å¹é³»Àå
  • gonadal steroid
    »ý½Ä»ù½ºÅ×·ÎÀ̵å
  • gonadal steroid-binding globulin
    »ý½Ä»ù½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • indirect tenderness =rebound t.
    °£Á¢¾Ð Åë(¡­äâ÷Ô).
  • indirect tenderness =rebound t.
    °£Á¢¾ÐÅë(¡­¾ÐÅë).
  • 17-ketogenic steroid
    17-ÄÉÅæÃ¼»ý¼º½ºÅ×·ÎÀ̵å
  • adrenal steroid
    ºÎ½Å½ºÅ×·ÎÀ̵å
  • adrenocortical steroid
    ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å
  • anabolic steroid
    ´Ü¹éµ¿È­Á¦
  • anabolic steroid
    ´Ü¹éµ¿È­½ºÅ×·ÎÀ̵å.
  • androgen, androgenic steroid
    ³²¼º(È­)È£¸£¸ó, ³²¼ºÈ­½ºÅ×·ÎÀ̵å.
  • Arthus phenomenon
    ¾Æ¸£Åõ½º Çö»ó(~ úÞßÚ)
  • Arthuss phenomenon
    ¾Æ¸£Åõ½ºÇö»ó
  • Bells phenomenon
    º§Çö»ó
  • CRST(Calcinosis, Raynauds phenomenon, Sclerodactyly, Telangiectasia) syndrome
    CRST ÁõÈıº.
  • Chameleon phenomenon
    Ä«¸á·¹¿ÂÇö»ó.
  • Danysz phenomenon
    Danysz Çö»ó
  • Danyszs phenomenon
    ´Ù´ÏÁî Çö»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • steroid rebound phenomenon
    ½ºÅ×·ÎÀÌµå ¹ÝµµÇö»ó(¡­ÚãÔ¯úÞßÚ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • indirect tenderness =rebound t.
    °£Á¢¾ÐÅë(¡­¾ÐÅë).
  • indirect tenderness =rebound t.
    °£Á¢¾Ð Åë(¡­äâ÷Ô).
  • rebound
    ¹Ýµ¿(ÚãÔÑ)
  • rebound hyperglycemia
    ¹Ýµ¿°íÇ÷´ç.
  • rebound hypertension
    ¹Ýµ¿¼º °íÇ÷¾Ð.
  • rebound nystagmus
    ¹Ýµ¿¾ÈÁø
  • rebound tenderness
    ¹Ýµ¿¾ÐÅë.
  • adrenal steroid
    ºÎ½Å½ºÅ×·ÎÀ̵å
  • adrenocortical steroid
    ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å
  • anabolic steroid
    ´Ü¹éµ¿È­Á¦
  • anabolic steroid
    ´Ü¹éµ¿È­½ºÅ×·ÎÀ̵å.
  • androgen, androgenic steroid
    ³²¼º(È­)È£¸£¸ó, ³²¼ºÈ­½ºÅ×·ÎÀ̵å.
  • cortical steroid
    ºÎ½ÅÇÇÁú½ºÅ×·ÎÀ̵å.
  • metabolic defect of steroid (adrenogenital syndrome)
    ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±â?
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Metabolic defect of steroid (Adrenogenital syndrome)
    ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
    [¿¾ ¿ë¾î] ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Sarle's phenomenon
    »ì·¹Çö»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Danysz phenomenon
    ´ë´ÏÁî Çö»ó(úÞßÚ)
  • ectrokinetic phenomenon
    °è¸éµ¿Àü±â Çö»ó(Í£ØüÔÑï³Ñ¨úÞßÚ)
  • plateau phenomenon
    Ç÷¡Åä Çö»ó(úÞßÚ)
  • adrenal cortical steroid
    ºÎ½ÅÇÇÁú½ºÅ×·ÎÀ̵å
  • alcoholic steroid
    ¾ËÄݼº(àõ) ½ºÅ×·ÎÀ̵å
  • anabolic steroid
    µ¿È­´ë»ç(ÔÒûùÓÛÞó)½ºÅ×·ÎÀ̵å
  • cardiotonic steroid
    °­½É(Ë­ãý) ½ºÅ×·ÎÀ̵å
  • catatoxic steroid
    µ¶¼º¹æ¾î(Ô¸àõÛÁåÝ) ½ºÅ×·ÎÀ̵å
  • sex steroid binding plasma protein
    ¼º(àõ)½ºÅ×·ÎÀÌµå °áÇÕ(Ì¿ùê) Ç÷Àå(úìíì) ´Ü¹éÁú(úìíìÓ±ÛÜòõ)
  • steroid
    ½ºÅ×·ÎÀ̵å
  • steroid alkaloids
    ½ºÅ×·ÎÀÌµå ¾ËÄ®·ÎÀ̵å
  • steroid alkaloid saponin
    ½ºÅ×·ÎÀÌµå ¾ËÄ®·ÎÀÌµå »çÆ÷´Ñ
  • steroid conjugate
    ½ºÅ×·ÎÀ̵å Á¢ÇÕü(ïÈùêô÷)
  • steroid diabetes
    ½ºÅ×·ÎÀÌµå ´ç´¢º´(ÓØÒãÜ»)
  • steroid hormone
    ½ºÅ×·ÎÀ̵å È£¸£¸ó
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • steroid
    ½ºÅ×·ÎÀ̵å
  • rebound
    ¹Ýµ¿¼º, ¹Ýµ¿Çö»ó
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    À¯ÀԴܸéÇö»ó
  • flare phenomenon
    Àå°³Çö»ó
  • Gibbs phenomenon
    ±é½ºÇö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • phenomenon
    Çö»ó
  • slice entry phenomenon
    ÀýÆíÀÔ±¸Çö»ó
  • sunset phenomenon
    ÀϸôÇö»ó
  • time of flight phenomenon
    À¯Ã¼¼Óµµ°­Á¶Çö»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RT Rebound Tenderness
T/RT Tenderness/Rebound Tenderness
PIR postinhibition rebound; protein identification resource
CREST Syndrome   1. Calcinosis cutis
  2. Raynaud's phenomenon
  3. Esophageal ...
CRST Syndrome   1. Calcinosis
  2. Raynaud's Phenomenon
  3. Sclerodactyly
...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PIR Postinhibitory rebound
PRP Primary Raynaud's Phenomenon
RP Raynaud Phenomenon
3 beta-HSD 3 beta hydroxy steroid dehydrogenase
3 beta-HSD 3 beta-hydroxy-steroid dehydrogenase/delta 5-delta 4 isomerase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • steroid rebound phenomenon
    ½ºÅ×·ÎÀÌµå ¹Ýµµ Çö»ó
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • rebound phenomenon
    ¹Ýµ¿ Çö»ó
    ¼Ò³ú ±â´É Àå¾Ö¿¡¼­ »çÁöÀÇ ±æÇ×±Ù »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀÇ Â¡Èķμ­, ȯÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇÏ°Ô Ä¡¸é Á¤»óÀÎ °æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Â µ¥ ºñÇÏ¿© ȯÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
  • rebound
    ¹Ýµ¿¼º
    ÀÚ±ØÀÇ Á¦°Å ½Ã¿¡ º¼¼ö ÀÖ´Â ¿ª¹æÇâÀÇ ¹ÝÀÀ.
  • rebound tenderness
    ¹Ýµ¿¼º ¾ÐÅë, ¹Ýµ¿ ¾ÐÅë
    ´©¸£´Â ÈûÀ» Á¦°ÅÇÒ ¶§¿¡ ´À³¢´Â µ¿Åë.
  • adrenal steroid
    ºÎ½Å ½ºÅ×·ÎÀ̵å
  • anabolic steroid
    ´Ü¹é µ¿È­ ½ºÅ×·ÎÀ̵å
  • C19 steroid
    C19 ½ºÅ×·ÎÀ̵å
  • endogenous steroid
    ³»¿ø¼º ½ºÅ×·ÎÀ̵å
  • steroid
    ½ºÅ×·ÎÀ̵å
    ½ºÅ×·ÎÀ̵å ÇÙ C7H8À» °¡Áö´Â È­ÇÕ¹°. ÄÝ·¹½ºÅ×·Ñ, ´ãÁó»ê, È£¸£¸ó µî »ýü ³»¿¡¼­ Áß¿äÇÑ ÀÛ¿ëÀ» ÇÏ´Â ¹°ÁúÀÌ Æ÷ÇԵȴÙ. ½ºÅ×·ÎÀ̵忡 ¼ÓÇÏ´Â È­ÇÕ¹°Àº ¿¹ÀüºÎÅÍ ¾Ë·ÁÁ® ÀÖ¾úÀ¸³ª 20¼¼±â ÃʺÎÅÍ °èÅëÀûÀÎ ¿¬±¸°¡ ÃßÁøµÇ¾î, 1932³â O. ·ÎÁ¨ÇÏÀÓ, H. Å·, H.O. ºô¶õÆ®°¡ ¸ðµÎ ½ÃŬ·Î ÆæÅ¸ ³ëÈ÷µå·ÎÆä³­Æ®·» °í¸®¸¦ °®´Â´Ù´Â °ÍÀ» È®ÀÎÇÏ¿´´Ù. ½ºÅ×·ÎÀ̵å°èÀÇ ¼º È£¸£¸óÀº »ýü ³»¿¡¼­ ±æÇ×Àû ¶Ç´Â Çùµ¿ÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¸öÀÇ Á¶ÀýÀ» À¯ÁöÇϰí Àִµ¥, ±¸Á¶»ó À¯»çÇÏ´Ù´Â °Í¸¸À¸·Î´Â ±× ÀÛ¿ëÀ» ¼³¸íÇÒ ¼ö ¾ø´Ù. µð¿¡Æ¿ ½ºÆ¿º£½ºÅç°ú °°Àº ÇÕ¼º ¾àǰµµ °­ÇÑ ¹ßÁ¤ È£¸£¸óÀÇ ÀÛ¿ëÀ» º¸ÀÌ´Â °ÍÀÌ ÀÖ¾î ³Î¸® ½Ç¿ëÈ­µÇ°í ÀÖ´Ù. ¶Ç ÄÚ¸£Æ¼¼Õ µî ºÎ½Å ÇÇÁú È£¸£¸ó¿¡´Â °­ÇÑ Ç׿°Áõ ÀÛ¿ëÀÌ ÀÖ¾î ÀǾàǰÀ¸·Î »ç¿ëµÇ°í ÀÖ´Ù. ´ãÁó»êÀº ¼ÒÈ­±â ³»¿¡¼­ ¹°¿¡ ³ìÁö ¾Ê´Â À½½Ä¹°À» ³ìÀ̸ç, ¼ÒÈ­, Èí¼ö¸¦ ½±°Ô ÇØÁÖ´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖÀ¸³ª ±× ÀÛ¿ë¿¡ ´ëÇØ¼­´Â Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù.
  • steroid anesthetic
    ½ºÅ×·ÎÀÌµå ¸¶ÃëÁ¦
  • steroid cover
    ½ºÅ×·ÎÀ̵å ÇǺ¹
  • steroid therpay
    ½ºÅ×·ÎÀÌµå ¿ä¹ý
  • topical steroid
    µµÆ÷¼º ½ºÅ×·ÎÀ̵å
  • aldosterone escape phenomenon
    ¾Ëµµ½ºÅ×·Ð ¹èÃâ Çö»ó
    ¼¼Æ÷ ¿Ü¾×ÀÌ ¾î´À Á¤µµ Áõ°¡Çϸé aldosteroneÀÇ ºÐºñ°¡ °è¼Ó Áõ°¡ÇÏ´õ¶óµµ ³ªÆ®·ýÀÇ ¹è¼³ÀÌ Áõ°¡ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ÀÌ Çö»óÀº ¼¼Æ÷ ¿Ü¾×ÀÇ Áõ°¡¿Í ÀϺδ ANH
  • aqueous-influx phenomenon
    ¹æ¼ö À¯ÀÔ Çö»ó
  • arthus phenomenon
    ¾Æ¸£Æ©½º Çö»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
rebound phenomenon Generally, any phenomenon in which a variable that has been displaced from its normal state by a disturbing influence temporarily deviates from normal in the opposite direction when the disturbing influence is suddenly removed, before finally stabilizing at its normal state, i.e., a phenomenon involving undershoot; e.g., the subsequent hypoglycaemia that may follow injection of glucose, because the initial hyperglycaemia caused excessive secretion of insulin.
Synonym: Stewart-Holmes sign
(05 Mar 2000)
rebound Just like a rebound in basketball when the ball reverses its course and bounces back off the backboard, in medicine a rebound is a reversal of response upon withdrawal of the stimulus.
(12 Dec 1998)
rebound effect The characteristic of a drug to produce reverse effects when either the effect of the drug has passed or when the patient no longer responds to the drug.
(18 Nov 1997)
anabolic steroid <endocrinology> A type of steroid hormone that stimulates the synthesis of protein. Anabolic steroids are compounds which stimulate the body into anabolism. This process involves the building of complex compounds from smaller simpler ones (for example proteins are built from amino acids). This process requires energy.
(13 Nov 1997)
receptors, steroid Proteins found usually in the cytoplasm or nucleus that specifically bind steroid hormones and trigger changes influencing the behaviour of cells. The steroid receptor-steroid hormone complex regulates the transcription of specific genes.
(12 Dec 1998)
gonadal steroid-binding globulin A protein that transports 65% of the testosterone in plasma.
Synonym: sex steroid-binding globulin.
(05 Mar 2000)
saturated steroid 6 alpha-hydroxylase <enzyme> Acts on 5 alpha-androstane-3 beta,17 beta-diol and 5 alpha-pregnan-3 beta-ol-20-one; does not require cytochrome p-450
Registry number: EC 1.14.99.-
Synonym: sat steroid 6alpha-hydroxylase
(26 Jun 1999)
sex steroid-binding globulin A protein that transports 65% of the testosterone in plasma.
Synonym: sex steroid-binding globulin.
(05 Mar 2000)
steroid A group name for lipids that contain a hydrogenated cyclopentanoperhydrophenanthrene ring system. Some of the substances included in this group are progesterone, adrenocortical hormones, the gonadal hormones, cardiac aglycones, bile acids, sterols (such as cholesterol), toad poisons, saponins and some of the carcinogenic hydrocarbons.
(18 Nov 1997)
steroid 11-alpha-hydroxylase <enzyme> Converts 11-deoxycortisol to 11-alpha cortisol (the 11-alpha isomer of hydrocortisone)
Registry number: EC 1.14.99.-
(26 Jun 1999)
steroid 11 beta-monooxygenase <enzyme> A steroid hydroxylase system found in adrenal tissues. It catalyses the 11-hydroxylation of steroids in the presence of molecular oxygen and consists of an NADPH-specific flavoprotein, a non-haem iron protein, and cytochrome p-450. Its deficiency is a cause of congenital adrenal hyperplasia (adrenal hyperplasia, congenital).
Chemical name: Steroid, reduced-adrenal-ferredoxin:oxygen oxidoreductase (11 beta-hydroxylating)
Registry number: EC 1.14.15.4
(12 Dec 1998)
steroid 12-monooxygenase <enzyme> A steroid hydroxylase found in liver microsomes. It catalyses the 12-hydroxylation of steroids in the presence of NADPH, cytochrome p-450, and molecular oxygen. It is an important enzyme in the synthesis of cholic acid from cholesterol in the liver.
Chemical name: Steroid, hydrogen-donor:oxygen oxidoreductase (12-alpha-hydroxylating)
Registry number: EC 1.14.99.-
(12 Dec 1998)
steroid 14-alpha-hydroxylase <enzyme> From induced vegetative cell cultures of mucor piriformis; hydroxylates progesterone to 14-alpha-hydroxyprogesterone in the presence of NADPH and oxygen
Registry number: EC 1.14.13.-
Synonym: progesterone 14-alpha-hydroxylase
(26 Jun 1999)
steroid 15-beta-hydroxylase <enzyme> Contains p-450 and ferredoxin; from bacillus megaterium
Registry number: EC 1.14.99.-
Synonym: cytochrome p-450 15 beta-hydroxylase, p-450 (15-beta), steroid-15 beta-monooxygenase, cytochrome p-450meg, cytochrome p4502c12, cyp2c12 protein
(26 Jun 1999)
steroid 17 alpha-monooxygenase <enzyme> A steroid hydroxylase system found in the microsomal membrane of the steroid-hormone producing tissues. It catalyses the 17-hydroxylation of steroids, such as progesterone or pregnenolone in the presence of NADPH and molecular oxygen. This is an important step in the biosynthesis of steroid hormones.
Chemical name: Steroid, hydrogen-donor:oxygen oxidoreductase (17 alpha-hydroxylating)
Registry number: EC 1.14.99.9
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • steroid
    ½ºÅ×·ÎÀ̵å
  • rebound
    µÇÆ¢´Ù
  • rebound
    (°ø µîÀÌ)µÇ Æ¢´Ù;(ÇàÀ§°¡)(Àڱ⿡°Ô·Î)µÇµ¹¾Æ¿À´Ù;(ÁÂÀý.½ÇÆÐ µî¿¡¼­)´Ù½Ã ÀϾ´Ù;¹ÝÇâÇÏ´Ù;µÇÆ¢°ÔÇÏ´Ù;µ¹ÀÌŰ´Ù;¹ÝÇâ½ÃŰ´Ù;µÇƦ;¹ÝÇâ;¹Ý¹ß;»ê¿ï¸²(echo);¹Ýµ¿(°¨Á¤µîÀÇ);¸®¹Ù¿îµå(º¼)
  • rebound
    REBINDÀÇ °ú°Å.°ú°ÅºÐ»ç
  • phenomenon
    »ç°Ç; Çö»ó
  • Raynaud's phenomenon
    ·¹À̳ë Çö»ó(¼ÕÀÇ ¼Òµ¿¸Æ ¼öÃà¿¡ ÀÇÇÑ ÀϽÃÀû Ç÷¾× ºÎÁ·À¸·Î ¼Õ°¡¶ô.¼ÕÀÇ ÀϺΰ¡ â¹éÇØ Áö´Â Çö»ó)
  • dellinger phenomenon
    µ¨¸°Àú Çö»ó 9
  • phenomenon
    Çö»ó;°æÀÌ;Áø±âÇÑ »ç¹°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á